ClinicalTrials.Veeva

Menu

Effect of Shexiang Tongxin Dropping Pills on Microcirculation in Patients With AMI

P

Peking University

Status and phase

Unknown
Phase 4

Conditions

Acute Myocardial Infarction

Treatments

Drug: Shexiang Tongxin Dropping Pills + routine treatment
Procedure: routine treatment

Study type

Interventional

Funder types

Other

Identifiers

NCT04952259
M2019480

Details and patient eligibility

About

This study is a randomized, controlled clinical trial. Evaluation of microcirculation resistance by index of microcirculation resistance to explore the protective effect of Shexiang Tongxin dripping pills on microcirculation in patients with acute anterior myocardial infarction.

Full description

Percutaneous coronary intervention (PCI) is the best way to improve the prognosis of patients with acute myocardial infarction (AMI), and ischemia-reperfusion injury (I/R) can damage the vascular endothelium through complex mechanisms, leading to microcirculation dysfunction and aggravation myocardial damage and affect the prognosis. Cell and animal experiments have proved that Shexiang Tongxin Dropping Pill has anti-inflammatory, anti-oxidant, reducing I/R damage, reducing infarct size, improving peripheral muscle microcirculation, and improving coronary slow blood flow, but it lacks directive evidences of improved coronary microcirculation in AMI patients. The microcirculation resistance index (IMR) is a parameter to evaluate the microcirculation state obtained by the pressure/temperature guidewire during PCI, which can accurately and quantitatively reflect the patient's coronary microcirculation state. In this study, patients with acute anterior wall elevation ST-segment myocardial infarction (STEMI) who were prospectively selected for direct PCI treatment were randomly divided into treatment group and control group. The treatment group was given Shexiang Tongxin Dropping Pills before PCI and received direct PCI treatment, the control group only received direct PCI treatment. The IMR of the two groups was detected immediately after PCI, and the differences in IMR values, myocardial injury markers and cardiac function parameters between the two groups were analyzed. It is hoped to prove that Shexiang Tongxin dripping pills have coronary microcirculation protection in acute anterior wall elevation ST-segment myocardial infarction with undergoing direct PCI treatment, and the effect is rapid, so as to provide a basis for optimizing AMI treatment strategies.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years old, no gender limit;
  • Anterior wall STEMI within 12 hours of onset (diagnostic criteria: ischemic chest pain lasting ≥30min; ST-segment elevation or new left bundle branch block in two or more adjacent leads on the ECG; with or without Elevated myocardial markers), emergency PCI treatment is planned;
  • Infarct-related coronary vascular anatomy is suitable for PCI treatment;
  • Agree and cooperate to participate in this research, and sign an informed consent form

Exclusion criteria

  • Past history of myocardial infarction history;
  • The arteries related to infarction have received PCI in the past;
  • Past CABG history;
  • Killip grade of cardiac function ≥ grade III or cardiogenic shock;
  • Systolic blood pressure ≤90mmHg;
  • Bradycardia, heart rate <60 beats/min, or atrioventricular block of degree II or more;
  • Allergic to Shexiang Tongxin Dropping Pills
  • Past history of asthma or severe COPD;
  • Severe liver and kidney dysfunction;
  • Participate in other clinical trials within 3 months;
  • Pregnancy or breastfeeding.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

Intervention group
Experimental group
Description:
Shexiang Tongxin dripping pills + routine treatment
Treatment:
Drug: Shexiang Tongxin Dropping Pills + routine treatment
Control group
Active Comparator group
Description:
routine treatment
Treatment:
Procedure: routine treatment

Trial contacts and locations

0

Loading...

Central trial contact

Liyun He

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems